Quest PharmaTech Inc (QPT) - Net Assets
Based on the latest financial reports, Quest PharmaTech Inc (QPT) has net assets worth CA$23.08 Million CAD (≈ $16.70 Million USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$24.33 Million ≈ $17.60 Million USD) and total liabilities (CA$1.25 Million ≈ $907.03K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Quest PharmaTech Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$23.08 Million |
| % of Total Assets | 94.85% |
| Annual Growth Rate | 16.8% |
| 5-Year Change | -87.79% |
| 10-Year Change | N/A |
| Growth Volatility | 280.33 |
Quest PharmaTech Inc - Net Assets Trend (1998–2025)
This chart illustrates how Quest PharmaTech Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Quest PharmaTech Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Quest PharmaTech Inc (1998–2025)
The table below shows the annual net assets of Quest PharmaTech Inc from 1998 to 2025. For live valuation and market cap data, see Quest PharmaTech Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | CA$21.40 Million ≈ $15.48 Million |
-7.59% |
| 2024-01-31 | CA$23.15 Million ≈ $16.75 Million |
-72.19% |
| 2023-01-31 | CA$83.25 Million ≈ $60.22 Million |
-7.91% |
| 2022-01-31 | CA$90.41 Million ≈ $65.40 Million |
-48.41% |
| 2021-01-31 | CA$175.22 Million ≈ $126.75 Million |
+1162.20% |
| 2020-01-31 | CA$-16.50 Million ≈ $-11.93 Million |
-280.60% |
| 2019-01-31 | CA$-4.33 Million ≈ $-3.14 Million |
-252.93% |
| 2018-01-31 | CA$2.83 Million ≈ $2.05 Million |
-73.34% |
| 2017-01-31 | CA$10.63 Million ≈ $7.69 Million |
+537.33% |
| 2016-01-31 | CA$-2.43 Million ≈ $-1.76 Million |
+34.90% |
| 2015-01-31 | CA$-3.73 Million ≈ $-2.70 Million |
-54.78% |
| 2014-01-31 | CA$-2.41 Million ≈ $-1.75 Million |
-847.44% |
| 1998-01-31 | CA$322.79K ≈ $233.50K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Quest PharmaTech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2074105600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$42.28 Million | 197.61% |
| Total Equity | CA$21.40 Million | 100.00% |
Quest PharmaTech Inc Competitors by Market Cap
The table below lists competitors of Quest PharmaTech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IQE PLC
LSE:IQE
|
$4.89 Million |
|
Wyncoast Industrial Park Public Company Limited
BK:WIN
|
$4.90 Million |
|
Hapbee Technologies Inc
V:HAPB
|
$4.90 Million |
|
Absolicon Solar Collector AB Series B
ST:ABSL-B
|
$4.90 Million |
|
Conferize A/S
CO:CONFRZ
|
$4.89 Million |
|
Cerillion PLC
LSE:CER
|
$4.89 Million |
|
Samchai Steel Industries Public Company Limited
BK:SAM
|
$4.89 Million |
|
Golden Metal Resources PLC
LSE:GMET
|
$4.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quest PharmaTech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,153,020 to 21,395,155, a change of -1,757,865 (-7.6%).
- Net loss of 1,801,058 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-1.80 Million | -8.42% |
| Other Changes | CA$43.19K | +0.2% |
| Total Change | CA$- | -7.59% |
Book Value vs Market Value Analysis
This analysis compares Quest PharmaTech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-01-31 | CA$-0.04 | CA$0.04 | x |
| 2019-01-31 | CA$-0.06 | CA$0.04 | x |
| 2020-01-31 | CA$-0.09 | CA$0.04 | x |
| 2021-01-31 | CA$1.04 | CA$0.04 | x |
| 2022-01-31 | CA$0.54 | CA$0.04 | x |
| 2023-01-31 | CA$0.49 | CA$0.04 | x |
| 2024-01-31 | CA$0.14 | CA$0.04 | x |
| 2025-01-31 | CA$0.13 | CA$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quest PharmaTech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-8.42%) is below the historical average (-6.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -24.81% | -1852.61% | 0.01x | 1.01x | CA$-112.35K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-31.07K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.45 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-4.40 Million |
| 2017 | -37.50% | -160934.92% | 0.00x | 1.03x | CA$-5.24 Million |
| 2018 | 0.00% | -13084.82% | 0.00x | 0.00x | CA$-4.35 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-3.37 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-4.65 Million |
| 2021 | 108.47% | 0.00% | 0.00x | 1.00x | CA$172.54 Million |
| 2022 | -94.06% | 0.00% | 0.00x | 1.01x | CA$-94.08 Million |
| 2023 | -8.81% | 0.00% | 0.00x | 1.01x | CA$-15.66 Million |
| 2024 | -13.04% | 0.00% | 0.00x | 1.06x | CA$-5.33 Million |
| 2025 | -8.42% | 0.00% | 0.00x | 1.05x | CA$-3.94 Million |
Industry Comparison
This section compares Quest PharmaTech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $24,209,535
- Average return on equity (ROE) among peers: -379.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quest PharmaTech Inc (QPT) | CA$23.08 Million | -24.81% | 0.05x | $4.89 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.